A paper published in Cell reveals that the PfSUB1 subtilisin-like serine protease is required for the exit of merozoites from infected erythrocytes. This enzyme is sequestered in exonemes ...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced regulatory approval has been ...
It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery.